(MedPage Today) — The FDA approved trastuzumab deruxtecan (T-DXd; Enhertu) in combination with pertuzumab (Perjeta) for the first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer.
Approval was based on results…
Source link : https://www.medpagetoday.com/hematologyoncology/breastcancer/119027
Author :
Publish date : 2025-12-15 21:28:00
Copyright for syndicated content belongs to the linked Source.
